Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

7 November 2025

Intellia disclosed that a patient who suffered severe liver toxicity in its Phase 3 MAGNITUDE trial has died; FDA clinical holds on MAGNITUDE and MAGNITUDE‑2 remain in place. ^[1]
NTLA shares traded sharply lower intraday as Wall Street cut targets; RBC lowered its price target to $9 and flagged an unfavorable near‑term risk/benefit profile for the ATTR program. ^[2]
Q3 2025 results show $669.9M in cash and securities (runway into mid‑2027), with progress continuing in Intellia’s hereditary angioedema (HAE) program lonvoguran ziclumeran (lonvo‑z; NTLA‑2002). ^[3]

What happened today

Intellia Therapeutics (NASDAQ: NTLA) is under intense pressure after the company said the patient who experienced Grade 4 liver enzyme and bilirubin elevations in its Phase 3 MAGNITUDE study later died. In a Nov. 6 business update, CEO John Leonard said the treating physician cited “complicating comorbidities,” and Intellia is working with investigators and outside experts on a risk‑mitigation plan for nexiguran ziclumeran (nex‑z; NTLA‑2001), its in vivo CRISPR therapy for transthyretin amyloidosis (ATTR). The FDA’s clinical holds on MAGNITUDE (ATTR‑CM) and MAGNITUDE‑2 (ATTR‑PN) are still in effect pending a formal hold letter. ^[4]

Sell‑side reaction was swift. RBC Capital Markets cut its NTLA price target to $9 from $14, pointing to the patient death and the availability of alternative ATTR treatments as reasons to reassess the program’s risk/benefit trade‑off. Other firms also trimmed ratings and targets following the pause and hold. ^[5]

What the latest data say about the trials

Intellia paused dosing and screening on Oct. 27 after reporting the severe liver toxicity event in MAGNITUDE; two days later the FDA imposed clinical holds on both late‑stage ATTR trials. At the time of the pause, >650 patients had been enrolled across MAGNITUDE and MAGNITUDE‑2, with >450 estimated to have been dosed. Today’s company update reiterates that the team is investigating mechanisms and developing mitigation steps. ^[6]

What is nex‑z? It’s an in vivo CRISPR/Cas9 therapy intended to knock down the TTR gene in the liver after a single dose. Intellia leads development in collaboration with Regeneron. The company plans to present longer‑term Phase 1 data for ATTR‑CM at AHA 2025 on Nov. 10, which could offer additional context on durability and safety. ^[7]

Earnings snapshot: liquidity and operating runway

Alongside the clinical update, Intellia posted Q3 2025 results:

Cash, cash equivalents & marketable securities:$669.9M (vs. $861.7M at year‑end 2024), including $114.5M raised via ATM in Q3.
Collaboration revenue:$13.8M (Q3 2024: $9.1M).
R&D expense:$94.7M (Q3 2024: $123.4M).
Net loss:$101.3M or ($0.92) per share (Q3 2024: ($1.34)).
Management guides that its balance sheet funds operations into mid‑2027 and, if timelines hold, through the anticipated U.S. launch of its HAE program. ^[8]

HAE program remains the counterweight

While ATTR is in the spotlight, Intellia emphasized continued progress for lonvoguran ziclumeran (lonvo‑z; NTLA‑2002) in hereditary angioedema. The Phase 3 HAELO trial finished enrollment in September, with top‑line data expected by mid‑2026 and a potential BLA submission in 2H 2026. Longer‑term Phase 1/2 data in HAE will be presented Nov. 8 at ACAAI 2025. None of these timelines were changed in the company’s Q3 update. ^[9]

Street debate: platform risk or asset‑specific?

A core investor question is whether MAGNITUDE’s liver events reflect platform‑wide risk (CRISPR editing and delivery) or drug‑specific biology. Recent coverage noted company officials believe the signal may be tied to the gene target rather than Intellia’s delivery platform; still, with proven alternatives in ATTR, analysts caution that the bar for safety is high as regulators review the hold. ^[10]

Near‑term catalysts and watch‑outs

FDA clinical hold letter for MAGNITUDE and MAGNITUDE‑2: clarity on next steps and any required protocol changes. ^[11]
Scientific readouts: AHA (Nov. 10) for ATTR‑CM Phase 1 durability/safety; ACAAI (Nov. 8) for HAE longer‑term data. ^[12]
Sell‑side updates: Expect more revisions to ratings/targets as details emerge from FDA correspondence and upcoming presentations. ^[13]

Bottom line

Today’s headline for NTLA is the MAGNITUDE patient death and the ongoing FDA holds. That development – and the Street’s reaction – now dominates the near‑term setup. Intellia’s cash runway and advancing HAE program provide strategic optionality, but investors will likely reserve judgment until the hold letter arrives and the company outlines a credible risk‑mitigation path for nex‑z. ^[14]

This article is for information only and not investment advice.

Sources: Company press releases and filings; major financial and biotech news outlets cited throughout.

ESGCT e-Seminars: Intellia’s Modular CRISPR/Cas9 Gene Editing Platform for the Treatment of Disease

Watch this video on YouTube.

References

1. www.globenewswire.com, 2. www.investing.com, 3. www.globenewswire.com, 4. www.globenewswire.com, 5. www.investing.com, 6. www.globenewswire.com, 7. www.globenewswire.com, 8. www.globenewswire.com, 9. www.globenewswire.com, 10. www.barrons.com, 11. www.reuters.com, 12. www.globenewswire.com, 13. www.investing.com, 14. www.globenewswire.com

Tags:

Mateusz Kaczmarek Latest posts

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

View all

Barclays Raises SiTime Target; Analysts Weigh In on SITM Stock
November 7, 2025, 2:40 PM EST. SiTime (SITM) jumped after Barclays raised its price objective from $220 to $260, though the firm still rates the stock underweight. The move follows a chorus of higher targets from peers: UBS ($355, buy), Stifel ($320, buy), and Raymond James ($270, outperform). Market commentary shows six Buy ratings vs. two Sell, with MarketBeat calling SITM a Moderate Buy at a $299.17 average target. The shares traded around $343 intraday on strong quarterly results: EPS of $0.87 on revenue of $83.6M, beating estimates, despite negative ROE and slim net margin. Year-over-year, revenue rose about 44.8%. Analysts poll for -2.44 EPS this year. Insider Fariborz Assaderaghi sold 3,000 shares, reducing ownership to about 90k shares.
Noteworthy ETF Inflow: Vanguard BIV Adds ~$570, 2.2% WoW
November 7, 2025, 2:38 PM EST. In ETF Channel's week-over-week check, the Vanguard Intermediate-Term Bond ETF (BIV) shows a notable inflow. An approximate $570 inflow equates to a roughly 2.2% rise in outstanding units. The update notes BIV trading near its 52-week high, with last trade around $78.06, in a $73.72-$78.91 year range. A comparison to the 200-day moving average is highlighted as a useful technical touchpoint. The write-up also reminds readers that ETFs trade like stocks but create or destroy units to meet demand, so weekly flows can reflect demand to purchase the underlying holdings. Overall, BIV appears to be attracting investor interest in this period.
Noteworthy ETF Inflows: VCLT - $1.5B Inflow, 14.7% WoW
November 7, 2025, 2:36 PM EST. Week-over-week, VCLT (the Vanguard Long-Term Corporate Bond ETF) shows a notable inflow of about $1.5 billion, a 14.7% increase in outstanding shares (from 126,754,711 to 145,354,711). The move comes with price context: last trade around $78.78, within a 52-week range of $67.47-$81.11. A look at the chart versus the 200-day moving average provides practical context for the trend. Creation of new units reflects demand and can imply buying pressure on the underlying holdings. Source data comes from ETF Channel's weekly flow update, with notes on ETF mechanics and unit creation.
Why Are Stock Markets Down Today? Key Drivers for Nasdaq, S&P 500 and Dow
November 7, 2025, 2:34 PM EST. U.S. stock indexes edged lower to start the session, on track for a weekly loss as the Nasdaq, S&P 500, and Dow slip. The S&P 500 fell about 0.5%, the Dow down roughly 174 points (-0.4%), and the Nasdaq -0.8%. The VIX rose to its highest in more than two weeks as investors weighed quarterly results, including a disappointing report from Block and a positive note for Peloton. Bond yields moved higher, while AI optimism has cooled amid concerns about monetization and spending in the sector. Tech names like Nvidia and Broadcom dropped, underscoring the sector's weekly declines. Airlines are feeling the pinch as the FAA trims air traffic; Tesla's big payout also weighed on sentiment. Market strategists cite traditional early-November weakness and limited catalysts.
Nasdaq 100 set for worst week since April meltdown as risk-off grips markets
November 7, 2025, 2:32 PM EST. Stocks joined a risk-off retreat on Friday, with the Nasdaq 100 on track for its worst week since the April downturn as a rout in AI names weighs on tech names. The S&P 500 faces a pause in gains after a consumer sentiment gauge hit a fresh three-year low, while megacaps in the Magnificent Seven slump. Investors fret valuations in high-flying AI stocks and watch for a dearth of official data amid a government shutdown, keeping markets sensitive to private payroll indicators. The Fed rate-cut outlook remains a focal point, even as a cooling labor market supports potential policy easing. Flows into U.S. equity funds held up for an eighth week, underscoring continued appetite despite volatility.